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Abstract  30 
Children and adolescents with overweight and obesity are a global health concern. This is an 31 
integrative overview of six Cochrane systematic reviews, providing an up to date synthesis of 32 
the evidence examining interventions for the treatment of children and adolescents with 33 
overweight or obesity. Data extraction and quality assessments for each review were 34 
conducted by one author and checked by a second. The six high quality reviews provide 35 
evidence on the effectiveness of  behaviour changing interventions conducted in children 36 
<6yrs (7 trials), 6-11yrs (70 trials), adolescents 12-17yrs (44 trials) and interventions that 37 
target only parents of children aged 5-11yrs (20 trials); in addition to interventions examining 38 
surgery (1 trial) and drugs (21 trials). Most of the evidence was derived from high income 39 
countries and published in the last two decades. Collectively the evidence suggests that 40 
multi-component behaviour changing interventions may be beneficial in achieving small 41 
reductions in body weight status in children of all ages, with low adverse event occurrence 42 
where reported. More research is required to understand which specific intervention 43 
components are most effective and in whom, and how best to maintain intervention effects. 44 
Evidence from surgical and drug interventions was too limited to make inferences about use 45 
and safety, and adverse events were a serious consideration.  46 
  47 
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Introduction 48 
Excess weight in children and adolescents is a growing public health crisis (1-3), with 49 
inequalities occurring in populations from different socioeconomic (4-6) and ethnic groups (7, 50 
8) (9, 10). 51 
Children and adolescents with obesity can develop a number of serious related 52 
comorbidities. These include musculoskeletal conditions (11), cardiovascular risk factors 53 
such as hypertension, insulin resistance, and hyperlipidaemia (12), respiratory conditions 54 
including sleep apnoea (13) or asthma (14), and digestive diseases such as non-alcoholic 55 
fatty liver disease (15). Psychosocial well-being can also be affected, with young people with 56 
obesity more susceptible to stigmatisation (16), reduced self-esteem and quality of life (17). 57 
Evidence also demonstrates that obesity in childhood tracks into adulthood (18, 19) thus 58 
increasing the risk of ill health later in life (20, 21). 59 
Given the complex nature of obesity, there is unlikely to ever be one treatment regime that 60 
will be effective across all populations, with the most suitable intervention approach 61 
determined by the child’s age and degree of excess weight, amongst other considerations. 62 
Treatment options range from lifestyle modification interventions, to the use of bariatric 63 
surgery and drugs. 64 
The least invasive and most widely used approach to treating obesity in childhood is lifestyle 65 
modification. These programmes aim to improve dietary quality, increase physical activity 66 
levels and reduce sedentary behaviours, often incorporating behaviour changing techniques 67 
to help sustain positive changes and prevent relapse. Many interventions have a family 68 
focus, with parents defined as the "agents for change”, particularly in children under 12 69 
years (27).  70 
Forms of bariatric surgery include gastric bypass, sleeve gastrectomy and gastric banding 71 
(22). Drugs used to treat obesity include: Sibutramine an appetite suppressant which, whilst 72 
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still licensed in Brazil, was suspended by the European Medicine Agency and withdrawn by 73 
the Food and Drug Administration (FDA) in 2010 due to adverse cardiovascular effects; 74 
Orlistat, a fat absorption inhibitor that has been approved by the FDA but only for children 75 
≥12 years old (23). Other drugs frequently used off license to treat obesity in childhood 76 
include: metformin, an anti-diabetic medication (24, 25) and fluoxetine, an antidepressant 77 
(26). New drugs targeting appetite regulation are currently under development or evaluation. 78 
 79 
The aim of this review was to conduct an integrative overview of six Cochrane reviews (28) 80 
(29) (30) (31) (32) (33), to provide a comprehensive update to the previous Cochrane review 81 
on interventions for treating obesity in children (34).  82 
This overview was written to help inform ongoing work by the World Health Organization on 83 
the management of children and adolescents with overweight and obesity. 84 
 85 
Methods  86 
We conducted this overview of reviews in accordance with the recommendations for 87 
Cochrane overviews of reviews (35). PROSPERO (CRD42016053423). All reviews 88 
produced to update the Oude Luttikhuis (2009) review (34) were included. 89 
A detailed description of the methods can be found in the online supplementary appendix 1. 90 
In brief, data was extracted using a standardised data collection form, and review quality 91 
was assessed using the revised Assessment of Multiple Systematic Reviews (R-AMSTAR) 92 
measurement tool (36), by one reviewer and checked for accuracy by a second reviewer, 93 
with disagreements resolved by consensus. Each R-AMSTAR assessment was conducted 94 
by reviewers who were not authors of the original review. 95 
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The primary outcomes of interest were changes in BMI or BMI-z score, with results from 96 
relevant meta-analyses extracted alongside secondary outcomes as reported in the 97 
summary of ﬁndings tables.  The original review authors’ Cochrane ‘risk of bias’ assessment 98 
(37) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) 99 
assessment were also extracted. 100 
Results 101 
Characteristics of included studies 102 
The characteristics of the six included reviews and the Randomised Controlled Trials (RCTs) 103 
included in each review are shown in the appendix: Tables S1 and S2 (online supplementary 104 
file), respectively. All six reviews were published between 2015 and 2017, and included 105 
RCTs with a minimum of six months data from baseline. Across all reviews a total of 163 106 
studies (19,756 participants) were included, representing trials conducted between 1968 and 107 
2016, from 30 countries. The vast majority of studies were undertaken in the USA (n=73, 108 
45%) or Europe (n=44, 27%), with only 16 (10%) studies conducted in upper-middle income 109 
countries, whilst the remainder were conducted in high income countries.1 Most studies were 110 
published within the last two decades.   111 
The number of trials included in each review varied substantially from just one trial included 112 
in the surgery review (28), to 70 trials included in the review of lifestyle interventions in 113 
children aged 6-11 years (32). Most trials were individually randomised, with a small number 114 
of cluster trials (n=11) across all six reviews. The median sample sizes for included studies 115 
within each review ranged from 50 to 96, with individual trial samples sizes within reviews 116 
ranging from just 10 to 686 participants. Participant views (e.g. satisfaction with, or opinions 117 
                                               
1 According to the World Bank list of economies (July 2016) 
http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS 
 
7 
 
of the intervention,) were not reported in any of the surgery or drug trials, and were only 118 
reported in 23 trials across the four lifestyle reviews. 119 
 120 
Participants 121 
Every review excluded children who were critically ill or diagnosed with a syndromic form of 122 
obesity. Where applicable, pregnant and breast feeding females were also excluded. All 123 
reviews included children with obesity, and the four lifestyle intervention reviews also 124 
examined children with overweight (median BMI-z score across the lifestyle reviews was 125 
between 2.2 and 2.3, although calculated using a variety of different growth references). The 126 
surgery and drug reviews included any child under the age of 18 years. A priori mean age 127 
groups were set for trials included in the lifestyle reviews to ensure each trial was only 128 
included in one review (the lifestyle interventions targeting the child and parent, or child 129 
alone were reviewed in the following age groups: up to 6, 6-11 and 12-17 years; for lifestyle 130 
interventions targeting the parent as the sole agent for change, an age range of 5-11 years 131 
was included). The median proportion of females in each review ranged from 54 to 65%, and 132 
reporting of socioeconomic status and ethnicity was limited.  133 
Interventions 134 
All reviews in this series examined the effectiveness of interventions that aimed to treat 135 
children or adolescents with overweight or obesity. One review (28) examined the 136 
effectiveness of bariatric surgery, another (29) studied drug interventions, whilst the 137 
remaining reviews (30-33) examined the effectiveness of lifestyle interventions that delivered 138 
diet, physical activity and behavioural interventions either as a single or multicomponent 139 
programme. Of these, Loveman (2015) (30) focused on parent only interventions whilst 140 
Colquitt (2016) (31), Mead (2017) (32) and Al-Khudairy (2017) (33) examined any lifestyle 141 
intervention by age group of the participating child. Interventions could be undertaken in any 142 
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setting, although more than half of the trials (n=85) were undertaken in either primary or 143 
secondary care.  144 
Comparators 145 
Comparators in each of the six reviews included true control (placebo or no intervention) 146 
(n=38), usual care (defined by either the study author or reviewer) (n=72) or an alternative 147 
concomitant therapy providing it was delivered in both the intervention and comparator arms 148 
(n=53).  149 
Outcome measures 150 
All six reviews examined the same primary outcome measures (BMI / BMI-z score, body 151 
weight and adverse events) and secondary outcome measures (health-related quality of life; 152 
self-esteem; all-cause mortality; morbidity; body fat distribution; behaviour change; 153 
participants' views of the intervention; socioeconomic effects).  154 
Methodological quality of included reviews  155 
The R-AMSTAR assessment results for each review are shown in supplementary appendix 156 
Table S3. All six reviews scored between 35 and 41, out of a possible 44, and were 157 
therefore deemed of good methodological quality. Areas where all reviews were marked 158 
down included not providing a clinical consensus statement and not adequately describing 159 
statistical tests.  160 
Risk of bias of included randomised controlled trials 161 
The bias associated with the included trials varied across the six reviews (Appendix Table 162 
S4, supplementary file). In general random sequence generation was rated as low risk of 163 
bias for the majority of included studies. Allocation concealment was generally rated low or 164 
unclear risk of bias.  Performance bias (i.e. not blinding study participants and personnel) 165 
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was rated as high or unclear risk for the majority of the non-drug trials. Detection bias (i.e. 166 
not blinding outcome assessment) varied across the reviews, with lower risk of bias for 167 
objective outcomes (which included body mass measurements). Attrition bias2 (i.e. 168 
incomplete data), was rated as unclear or high risk, in over half of all trials included in each 169 
review. Selective reporting bias (i.e. differences between reported and unreported findings) 170 
was generally poor in a large proportion of trials in each review. The proportion of trials with 171 
low risk of other biases varied across the reviews. 172 
Quality of evidence from randomised controlled trials in 173 
the included reviews 174 
Each of the six reviews assessed overall quality of the evidence using the GRADE method 175 
which is shown in the summary of findings (Supplementary appendix: Tables S5A-E,). 176 
Overall the quality of the evidence was low for BMI and, where provided, was very low or low 177 
for other outcomes measured in the reviews. No studies provided data on socioeconomic 178 
effects. Reasons for downgrading BMI evidence included: high risk of bias (e.g. attrition), 179 
imprecision (wide confidence intervals), and inconsistency (heterogeneity). 180 
Effects of interventions  181 
Summary of findings (Supplementary appendix: Tables S5A-E), and BMI and BMI-z score 182 
outcome analyses (Supplementary appendix: Table S6) are presenting in the supplementary 183 
file.  184 
 185 
Lifestyle interventions for the treatment of overweight or obesity 186 
                                               
2 Attrition bias was determined by assessing the completeness of the outcome data including attrition and 
exclusions from the analysis. 
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The vast majority of evidence (141 out of 163 trials) reviewed in this overview were lifestyle 187 
interventions (i.e. those that addressed diet, physical activity and / or behaviour change). 188 
This evidence was assessed across four reviews, examining the effectiveness of 189 
interventions delivered to the child, or parent and child across infancy, pre adolescence and 190 
adolescence. This was supplemented by a further review that specifically examined 191 
interventions that targeted parents as the sole agent for change in their child.  The results 192 
are summarised below. 193 
Interventions for pre-school children up to the age of 6 years  194 
Colquitt et al (2016) (31) conducted searches up to March 2015 and identified seven 195 
completed and four ongoing trials. Of the seven completed trials (923 participants), six 196 
tested multicomponent interventions and one tested a dietary intervention. Trials were 197 
undertaken in four countries (one upper-middle income) in a variety of settings, and all were 198 
published from 2009. The mean age of participants ranged from 2 to 5 years, and the 199 
median of the mean baseline BMI-z score was 2.25.  The proportion of female and white 200 
participants ranged from 25-80% and 47-91%, respectively. The duration and nature of the 201 
intervention and comparators varied across the studies, and whilst all seven trials reported a 202 
period of post intervention follow up ranging in duration from 6 to 32 months, follow up data 203 
was only available for five studies.  204 
When the multicomponent interventions were compared with control (usual care, enhanced 205 
usual care, or information provision) at the end of the intervention (6 to 12 months), a 206 
reduction in BMI-z score was observed in favour of the intervention: mean difference (MD) -207 
0.3 units (95% CI: -0.4 to -0.2) (210 participants; four trials). This reduction was maintained 208 
at both 12 to 18 months follow-up from baseline (6 to 8 months post intervention) (MD -0.4 209 
units (95% CI: -0.6 to -0.2); 202 participants; four trials), and at 2 years follow-up from 210 
baseline (12 months post intervention) (MD -0.3 units (95% CI: -0.4 to -0.1); 96 participants; 211 
one trial). Three out of the four multicomponent studies also assessed parental weight 212 
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change (parents were required to have a BMI of least 25 or 27 kg/m2 to be included). 213 
Results from the parental weight change analysis revealed an overall mean difference of -214 
4.69 kg (95% CI: -7.27 to -2.11) in favour of the intervention, measured at the end of the 215 
intervention (three trials, 146 participants, low quality evidence). This reduction appeared to 216 
be sustained at 12 to 24 months follow up (6 to 12 months post intervention). 217 
Only one very low quality trial examined the effectiveness of an energy restricted (57 218 
participants) and dairy rich (59 participants) diets, and reported a small reduction in BMI-z 219 
score (MD -0.1 units [95% CI: -0.11 to -0.09]), but this reduction was maintained at 36 220 
months in only the dairy rich arm. Only one trial documented adverse events stating that 221 
none had occurred. Three trials reported health-related quality of life, with improvement 222 
shown in some, but not all domains, whilst behaviour change and parent-child relationships 223 
were reported inconsistently. No data was reported for all-cause mortality, morbidity, and 224 
socio-economic effects. 225 
A large cluster RCT (n=475) was included in the review but not included in the meta-analysis 226 
due to possible methodological bias. This trial demonstrated a statistically non-significant 227 
change in BMI-z score (MD: -0.05 units [95% CI: -0.14 to 0.04]) over the one year 228 
intervention (no post intervention follow up data was provided). 229 
Interventions for school aged children under 12 years 230 
Lifestyle interventions targeting parents as the sole agents for change: 231 
Loveman et al (2015) (30) conducted searches up to March 2015, and identified 20 trials and 232 
ten ongoing studies. The 20 trials comprised of 3057 participants, and reported a median 233 
mean baseline age of 8 years, a median female proportion of ~60%, and where reported a 234 
median baseline BMI-z score of 2.2 in the intervention group and 2.3 in the control group. 235 
The proportion of white participants ranged from 54-100%. All but one trial were published 236 
from 2000 onwards, and were conducted in seven countries (one upper middle income). The 237 
sample size of individual trials ranged from 15 to 645 and the duration of the intervention 238 
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ranged from 2.25 to 24 months. All but three trials included a period of post intervention 239 
follow up ranging from 2.75 to 18.5 months, giving rise to a follow up from baseline ranging 240 
from 5.5 to 24 months. Whilst the content of the interventions varied considerably, the 241 
comparators also differed, and so the outcomes were meta-analysed by comparator group.  242 
BMI-z score was the most frequently reported outcome measure. The mean difference in 243 
BMI-z score at longest follow up (10 to 24 months) was -0.04 units (95% CI: -0.15 to 0.08) 244 
for three trials (267 participants) comparing parent-only intervention with parent child 245 
intervention. A similar statistically non-significant change in BMI-z score was seen when 246 
comparing parent-only interventions to minimal contact control interventions at the longest 247 
follow-up period (9 to 12 months), with a mean difference of -0.01 units (95% CI: -0.07 to 248 
0.09) (one trial, 165 participants). For the two trials (136 participants) comparing parent-only 249 
interventions with a waiting list control, a statistically significant change in BMI-z score was 250 
observed in favour of the intervention at the longest follow-up period (10 to 12 months) with 251 
a mean difference of -0.10 units (95% CI: -0.19 to -0.01). Where the comparator was a 252 
concomitant intervention, no meta-analysis was reported due to a very high degree of 253 
heterogeneity (I2=94%).  254 
Secondary outcomes reported in the summary of findings table included parent-child 255 
relationships which were assessed in three studies (low quality evidence): two demonstrated 256 
a small effect in favour of the parent only intervention and one showed no effect. Whilst two 257 
studies reported that no serious adverse events occurred, generally adverse events were not 258 
reported. Data on morbidity, all-cause mortality and socioeconomic effects were not 259 
reported. 260 
 261 
Lifestyle interventions targeting the child-only, or child and parent:  262 
Mead et al (2017) (32), conducted searches up to July 2016 and identified 70 trials (8,461 263 
participants), four of which were cluster trials, and 20 ongoing studies. Although the vast 264 
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majority of trials included both the child and parent/care giver (n=65) and comprised a 265 
dietary, physical activity and behavioural component (n=49), the delivery and content of the 266 
interventions varied considerably. Individual trial sample sizes ranged from 16 to 686 267 
participants, with a median mean age of 10 years at baseline (with only 15 trials including 268 
participants with a mean age of <9 years). The median proportion of female participants was 269 
approximately 55% (ranging from 26 to 100%). Where reported, the median proportion of 270 
white participants was 80% and 71% in the intervention and control arms, respectively 271 
(ranging from 0 to 100%). Median of the mean BMI-z score at baseline was 2.2 (ranging 272 
from 1.3 to 5.6), the duration of the interventions ranged from 0.25-24 months, and follow up 273 
from baseline ranged from 5.5-36 months. Just over half of the trials (n=37) had a period of 274 
post intervention follow up, with a median duration of 10 months. 275 
The majority of trials (n=63) were published from 2000. Trials took place in 18 high income 276 
countries and three upper-middle income countries. Setting varied significantly across 277 
studies, although half (n=36) took place in primary or secondary care. Fifteen trials 278 
evaluated an additional element as part of a concomitant intervention, and were 279 
consequently analysed separately. A further two separate analyses were also conducted for 280 
the four cluster trials and two maintenance trials. Of these separately assessed trials, two of 281 
the clusters were subject to methodological queries which precluded them from analysis, 282 
and the remaining studies did not demonstrate any substantial impact on BMI. 283 
Twenty four trials reporting BMI could be pooled for analysis, and demonstrated a change in 284 
BMI in favour of the intervention (measured at last available point of follow up) of -0.53 kg/m2 285 
(95% CI: -0.82 to -0.24); 2785 participants). Thirty-seven trials reported BMI-z score suitable 286 
for meta-analysis, which resulted in a change in favour of intervention (measured at last 287 
available point of follow up) of -0.06 units, (95% CI: -0.10 to -0.02); 4019 participants).  288 
As the main meta-analyses revealed significant heterogeneity, subgroup analyses were 289 
conducted to examine the impact of: type of intervention, type of comparator, risk of attrition 290 
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bias, setting of intervention, duration of post intervention follow up period, parental 291 
involvement and severe obesity at baseline. None of the subgroup analyses gave rise to a 292 
consistent effect that differed significantly from the overall pooled effect for both BMI and 293 
BMI-z score. However, subgroup analysis of BMI by duration of post intervention follow up 294 
period (no post intervention follow up [15 trials] vs follow up at: <6 [3 trials], 6-12 [2 trials] 295 
and >12 [4 trials] months) demonstrated that intervention effects only remained significant 296 
immediately post intervention. A similar pattern was also observed for BMI-z score although 297 
it did not reach significance. These findings align with data from the two trials (263 298 
participants) identified in this review that specifically examined the impact of a post 299 
intervention maintenance period on BMI-z score and found no significant intervention effect.   300 
Thirty one trials documented whether serious adverse events occurred, although the vast 301 
majority (n=29) reported zero occurrence. In the two trials that reported a serious adverse 302 
event occurrence, examples included influenza, muscular-skeletal surgery or injuries, 303 
however none were considered to be related to the study.  Six trials reported a range of 304 
adverse events in a small percentage of participants (examples included elevated 305 
triglycerides, blood pressure and cholesterol in both groups in one trial, and a range of 306 
accidents, infections, and skin rashes across groups, none of which were deemed to be 307 
related to the trial). Only a small number of trials reported secondary outcomes with data 308 
suitable for meta-analysis: parent reported and child reported health-related quality of life 309 
was reported in five trials (718 participants) and three trials (164 participants) respectively; 310 
two trials reported on self–esteem (144 participants); two trials (168 participants) reported 311 
change in caloric intake; and six trials (744 participants) reported accelerometry measured 312 
physical activity. However, none of the analyses demonstrated a significant difference 313 
between intervention and control. Two trials (55 participants) reported minutes per day of TV 314 
viewing, and found a small significant reduction of 6.6 mins per day in favour of the 315 
intervention. Data on morbidity, all-cause mortality and socioeconomic effects were not 316 
reported. 317 
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Interventions for children 12 years and older  318 
Al-Khudairy et al (2017) (33) conducted searches up to July 2016, and 44 trials (4781 319 
participants; median mean age at baseline: 14.3 years), and 50 ongoing studies were 320 
identified. All studies (apart from two) were published between 2000 and 2017, and were 321 
conducted in 15 countries (with five trials conducted in four upper-middle income countries). 322 
The duration of the interventions ranged from 6 weeks to 2 years, with follow up from 323 
baseline ranging from 24 weeks to 2 years, with a post intervention follow up period (median 324 
length 6 months; range 1-21 months) in just over half of all studies. The setting and content 325 
of the interventions varied considerably across the trials; five trials focused solely on physical 326 
activity interventions, five on diet only interventions, and 34 on multicomponent interventions. 327 
Sample size ranged from 10 to 521 participants. Median of the mean (and range) baseline 328 
BMI and BMI-z score across the studies in the intervention groups were 32.4 kg/m2 (26.6-329 
45.5 kg/m2) and 2.2 units (1.92-4.2 units) respectively, and in the control groups 31.84 kg/m2 330 
(26.6-45.5 kg/m2) and 2.2 units (1.81-4.3 units), respectively. The median proportion of 331 
female participants was 55.8% in the intervention groups and 54.5% in the controls (ranging 332 
from 0-100%); in the 19 trials reporting ethnicity, the proportion and range of white 333 
participants was 58.8% for the intervention groups and 34.8% for the controls (ranging from 334 
0-100%).  335 
For the trials that could be pooled for meta-analysis, the overall mean difference in change in 336 
BMI at the last available measurement point was -1.18 kg/m2 (95% CI: -1.67 to -0.69) (2774 337 
participants; 28 trials), whilst the change in BMI-z score was -0.13 units (95% CI: -0.21 to -338 
0.05) (2399 participants; 20 trials). This reduction remained when examined in those trials 339 
with long (18-24 months) follow-up from baseline: BMI -1.49 kg/m2 (95 CI: -2.56 to -0.41) 340 
(760 participants; six trials) and BMI-z score -0.34 units (95% CI: -0.66 to -0.02) (602 341 
participants; five trials). As expected intervention effects were larger when compared to no 342 
intervention or usual care, than those compared to concomitant interventions. The length of 343 
the post intervention follow-up period had no significant effects on BMI. Further subgroup 344 
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analyses revealed that the type of intervention (multicomponent, physical activity only or diet 345 
only) had little effect on outcomes although the vast majority of trials were multicomponent. 346 
Similarly, parental involvement in the intervention, the intervention setting, mode, and 347 
theoretical basis of intervention did not significantly alter the overall effect estimates. Only 348 
five trials documented adverse events, three of which reported no events; one stated 6.4% 349 
of participants experienced an adverse event (but no further details provided) and only one 350 
reported the occurrence of adverse events documented as ranging from 19-25%. Seven 351 
trials (972 participants) demonstrated an improvement in health-related quality of life at a 352 
follow up of 6-24 months (SMD 0.44 (95% CI: 0.09 to 0.79)). Lifestyle related behaviours 353 
were measured too inconsistently to summarise, whilst measures of all-cause mortality, 354 
morbidity and socioeconomic effects were not reported.  355 
 356 
Drug interventions for the treatment of obesity in children and 357 
adolescents  358 
Mead et al (2016) (29) conducted searches up to March 2016 and identified 21 trials (11 359 
metformin [including one trial arm with Metformin and Fluoxetine], six Sibutramine, four 360 
Orlistat), and eight ongoing studies. Duration of the interventions ranged from 2.75 to 12.5 361 
months, with duration of follow up (from baseline) ranging from 5.5 to 23 months. It is 362 
important to note that only four trials reported post intervention follow up. In total 2484 363 
children (mean baseline age range 10-16 years [median 13.7 years], mean baseline BMI 364 
range 26-42 kg/m2 [median approximately 35 kg/m2]) participated in the included trials, which 365 
were undertaken in secondary care settings and conducted in the last two decades (1999-366 
2010). The trials took place in twelve different countries (four upper-middle income) with an 367 
individual trial sample size ranging from 24 to 539 participants, and completion rates ranging 368 
from 36 to 100% (median 78.6%).  369 
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Eighteen trials were placebo controlled, and 17 of these also included a concomitant lifestyle 370 
intervention. Ethnicity was clearly reported in 10 out of the 21 trials with the proportion of 371 
white participants ranging from 37 to 92%. BMI was meta-analysed for 16 trials (1884 372 
participants) at 6 months (14 trials) and 12 months (two trials), which was the end of the 373 
active intervention in all but one trial. A small but statistically significant mean difference in 374 
BMI was observed: -1.3 kg/m2 (95% CI: -1.9 to -0.8) in favour of the intervention. When 375 
these data were analysed by drug type, Sibutramine, Metformin and Orlistat all 376 
demonstrated a reduction in BMI. Additional subgroup analyses indicated statistically 377 
significant differences, favouring studies with higher dropout and from middle income 378 
countries. The most common adverse events were: gastrointestinal in the Orlistat and 379 
Metformin trials; and tachycardia, constipation and hypertension in the Sibutramine trials. 380 
Serious adverse events were reported in five trials (1347 participants) resulting in a relative 381 
risk of 1.43 (95% CI: 0.63 to 3.25). Health-related quality of life was only reported in two 382 
trials (86 participants), with no significant between group differences seen in the trial 383 
reporting findings from the SF36 health questionnaire. One suicide was reported in an 384 
Orlistat group. Morbidity was reported in only one trial (533 participants) resulting in a small 385 
between group difference in new gallstone development in an Orlistat arm. Data on 386 
socioeconomic effects were not reported. 387 
Surgery for the treatment of obesity in children and adolescents  388 
Ells et al (2015) (28) conducted searches up to March 2015, and identified one recent 389 
Australian RCT examining the effectiveness of a laparoscopic adjustable band compared to 390 
a multicomponent lifestyle intervention (usual care). Fifty predominantly female adolescent 391 
participants with severe obesity (mean age 16 years, mean BMI over 40), took part in the 392 
trial. Between baseline and last point of measurement (24 months) participants in the 393 
surgery arm experienced a significant 12.7kg/m2 (95% CI: 11.3 to 14.2) reduction in BMI 394 
compared to a reduction of 1.3kg/m2 (95% CI: 0.4 to 2.9) in the control arm. The surgery 395 
participants also experienced improvements in two of eight quality of life concepts, when 396 
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compared to the control. Post intervention morbidity (metabolic syndrome) was reported in 397 
four patients completing the control arm and no patients in the intervention arm. No other 398 
secondary outcome data were reported. Four ongoing studies were identified which may 399 
help strengthen future evidence for surgery interventions in this population group. 400 
 401 
Discussion  402 
This overview provides a comprehensive update to Oude Luttikhuis, 2009 (34). However, 403 
despite a dramatic increase in the number of trials conducted over the last eight years, 404 
overall the findings remain similar. The outcomes also align with more recent systematic 405 
reviews of parent only interventions (38, 39); educational interventions to treat obesity in 6 to 406 
12 year old children (40); school based interventions (41) and lifestyle interventions for 407 
children up to 18 years (42). BMI-z score change by age group also followed a similar 408 
pattern to changes reported in a recent observational study (43). 409 
 410 
All six reviews provided good quality evidence with high R-AMSTAR scores, thus providing a 411 
high degree of confidence in the review findings and clinical relevance (36). However the 412 
overall quality of the trials included in the reviews was low, with improvement required 413 
across most of the risk of bias domains, but in particular attrition and selective reporting. 414 
Performance bias was also an identified risk in many of the non-drug trials, reflecting the 415 
difficulties in blinding lifestyle and surgical interventions.  416 
 417 
Implications for research  418 
Despite a sizeable evidence base, there remain a number of important gaps (Table 1). 419 
Therefore, serious consideration should be given to ensuring all new trials follow the 420 
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CONSORT criteria, use standardised outcome assessment criteria and validated 421 
measurement tools, to facilitate comparisons across trials. Trials co-ordinators should also 422 
ensure that long term (>12 month) post intervention follow ups are conducted, and details on 423 
all adverse events and maintenance periods are clearly and consistently reported. Authors 424 
should use the TIDieR checklist (44) to provide comprehensive and reproducible trial 425 
descriptions (clearly describing both the control and intervention conditions, given the 426 
differences that can arise in usual care provision), and must ensure: 1) trials are adequately 427 
powered; 2) attrition is accounted for in an appropriate intention to treat analysis (i.e. the use 428 
of multiple imputation); 3) intervention cost is included; and 4) where possible study 429 
personnel are blinded. 430 
Conducting more qualitative research to understand the barriers and facilitators to weight 431 
management in different populations would be advantageous, as would more process 432 
evaluations (45). These studies may help guide implementation, tailor interventions to 433 
populations needs, and understand which approaches may work better for which populations 434 
and why.  435 
 436 
Implications for practice  437 
It is important to note that the vast majority of the evidence was generated in high income 438 
countries, thus calling into question the generalisability of these findings in low and middle 439 
income countries. This is particularly important given the most rapid recent rises in 440 
overweight in young children from low and lower-middle income countries (1), and lack of 441 
cost-effectiveness data, making it difficult to effectively translate findings for lower income 442 
countries with potentially different health and political economies.  443 
Only one trial of bariatric surgery was identified which provides insufficient evidence to 444 
assess the wider applicability and acceptability of this approach. A recent non-RCT study 445 
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including 242 adolescents undergoing bariatric surgery at five U.S. centres reported 446 
significant improvements in weight, cardio-metabolic health, and weight-related quality of life 447 
3 years post-surgery. However, associated risks included specific micronutrient deficiencies 448 
and the need for additional abdominal procedures (46). A recent French review, concluded 449 
that bariatric surgery is not a simple surgical intervention in teenagers, with minor side 450 
effects reported in 10-15%, and severe side effects in 1-5% (47).  451 
Drug interventions were also assessed, however, some of the trial drugs were used off 452 
license, or have been withdrawn in some countries, which coupled to the lack of long term 453 
follow up and safety data, makes it impossible to make any conclusive recommendations.  454 
From the lifestyle modification reviews, the largest (0.3 unit) BMI-z score reduction was 455 
observed in the interventions targeting the youngest children (2-5 years), although this was 456 
by far the smallest evidence base. However, given the tracking of excess weight into later 457 
childhood (48, 49) it is important to observe the effectiveness of early intervention to help 458 
prevent excess weight persisting into later childhood. Early treatment may also be important 459 
given the smallest overall reduction in BMI-z score (0.06 units) was observed in interventions 460 
delivered to children aged 6-11 years. This finding may reflect the challenges of intervening 461 
in this age group, who may be more influenced by the wider obesogenic environment than 462 
their younger counterparts. This age group may also be less autonomous than their older 463 
adolescent peers and may therefore rely more on parental support, yet the exact role of 464 
parents and parental weight status is not clearly described. This finding warrants further 465 
consideration given the association between parental and child obesity (50). 466 
Whilst any reduction in BMI-z score for children with overweight and obesity may be of 467 
clinical benefit, the BMI-z score reduction required to ameliorate any comorbidities is less 468 
clear. For example, a small observational study in young people (median age 12.4 years) 469 
with severe obesity reported that a reduction of 0.25 BMI-z score units was required to 470 
improve adiposity and metabolic health (51). However, improvements in cholesterol were 471 
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observed in children with obesity aged 7-17 years with a BMI-z score reduction of <0.1 unit 472 
(52), and improvement in insulin and cholesterol was observed in 5-19 year olds with 473 
obesity, following a BMI-z score reduction of 0.15 (SD 0.5) units (53). Reduction of systemic 474 
blood pressure and arterial stiffness was also reported in pre-pubertal children with obesity 475 
following a BMI-z score reduction of 0.1 unit (54). The differences in BMI-z score associated 476 
cardio-metabolic changes may also be affected by the use of different reference populations 477 
used to calculate the BMI-z score (Farpour-Lambert personal communication). In addition to 478 
any clinical benefit, it is important to consider the public health benefits of even small 479 
BMI/BMI-z score reductions if feasibly achieved across an entire population (55).  480 
 481 
As BMI it is not a direct measure of body composition, changes in fat mass may be 482 
confounded with changes in fat-free mass. This is particularly important given data from the 483 
UK (56), US (57) and Australia (58) demonstrates increases in central adiposity exceeding 484 
increases in BMI in children. Although other body composition measures were not the focus 485 
of this overview given variations in the use, cost and precision, each review did show (as a 486 
secondary outcome) other body composition indices were reported in the individual trials. 487 
Waist circumference was the most frequently reported measure however, meta-analyses of 488 
this outcome were only reported in the reviews of children (32) 6-11years (ﬁnal follow-up: 489 
MD -2.41 cm, 95% CI -3.59 to -1.23; P < 0.0001; 11 trials; 1325 participants) and 12-17years 490 
(33) (final follow up: MD -2.26 cm, 95% CI -3.80 to -0.72; P = 0.004; 17 trials; 1997 491 
participants), thus demonstrating a parallel reduction in waist circumference and BMI as a 492 
result of lifestyle interventions in school age children.  493 
 494 
Although intervention content, format and delivery varied significantly both within and across 495 
the included reviews, collectively there was evidence to support the role of multicomponent 496 
interventions. There was also no clear difference in terms of outcome according to setting, 497 
which may suggest that intervention content and wider context may be more important than 498 
delivery setting. Very little data were provided on the role of the family characteristics or the 499 
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wider environment. Although the inclusion of parents in both the school age (6-11 years) and 500 
adolescent (12-17 years) studies did not appear to significantly impact on the overall effect 501 
of the intervention, specifically targeting children and parents with overweight in the 502 
preschool (up to 6 years) review seemed to demonstrate a dual benefit to both children and 503 
their parents. Workniak et al (59) also showed that parental weight status change was an 504 
independent predictor of child weight status change in a family based weight management 505 
study of children 8-12 years. Parents have an important role in controlling their child’s food 506 
and activity environment, helping their child attend treatment sessions and implement 507 
changes. Thus intensity of parental involvement (60) and their role as an influential role 508 
models (61), may all be important contributors to effective long term paediatric weight 509 
management.  510 
The sustainability of any observed reduction in BMI/BMI-z score is a key consideration. 511 
Whilst effects appeared to be sustained in the adolescent and preschool aged children, data 512 
from children aged 6-11 suggests effects were not sustainable. Given obesity is a chronic 513 
relapsing disease (62) manifested in an obesity conducive environment, it is perhaps 514 
unsurprising that short term effects do not persist particularly in children who may be most 515 
influenced by their wider environment.  516 
Data on adverse events were generally not well reported across the studies in any of the 517 
lifestyle reviews, but where reported occurrence was low. However adverse events such as 518 
effects on linear growth, injuries, eating disorders and psycho-social well-being must be 519 
considered. Bariatric surgery is a major surgical intervention, with serious potential risks for 520 
operative and perioperative complications and mortality. The restrictive or mal-absorptive 521 
nature of some forms of bariatric surgery presents an additional consideration in growing 522 
children. Psychological maturity, ability to provide informed consent, the availability of family 523 
support, and provision of ongoing post-operative lifestyle support (63) should be considered. 524 
Drug interventions are also not without adverse events, which depending on the drug 525 
prescribed, include a variety of gastrointestinal and cardiovascular conditions.  526 
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In summary, this overview provides a comprehensive update on the effectiveness of obesity 527 
treatments for children 2-18 years. However, it is essential that when translated into practice, 528 
findings are interpreted within the context of local political and health systems, and 529 
population needs (Table 2). It is also important to acknowledge the limitations of RCT 530 
evidence when evaluating complex interventions. It may therefore be important to consider 531 
additional observational studies, where gaps remain in the RCT evidence. 532 
  533 
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Table 1: Outstanding research questions 534 
What weight management interventions are most effective in low and middle income 
countries? 
What weight management interventions are most effective for children with disabilities, 
complex health needs or very severe forms of obesity? 
What weight management interventions are most effective in specific ethnic, religious and 
culturally diverse groups? 
How cost effective are child and adolescent weight management programmes?  
What are the key intervention components that promote success? 
What are the key family characteristics/environments that promote success? 
What is the optimal role of parents within different age groups? 
What behaviour change strategies are most useful? 
What maintenance programmes are required to help improve the sustainability of positive 
weight management improvements?  
What are the benefits of dual family weight management i.e. interventions that address 
weight management in overweight children and overweight parents simultaneously in the 
same intervention?  
What are the impacts of emerging new technologies such as e-health in children? 
What are the long term benefits, and safety of drug interventions in children and adolescents 
with obesity? 
How clinically effective is restrictive or mal-absorptive bariatric surgery in treating obesity in 
adolescents from different backgrounds? 
 535 
  536 
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Table 2: Practical considerations when implementing findings in practice. 537 
Evidence from surgical and drug RCTs was too limited to make inferences about use and 
safety, and adverse events were a serious consideration.  
 
Lifestyle interventions can be successful in producing small reductions in BMI-z score with 
relatively low occurrence of adverse events. However obesity is a chronic relapsing 
condition, therefore it may be challenging to sustain changes over the longer term, thus 
ongoing maintenance support will be required. 
 
As there is currently insufficient evidence to suggest which particular setting or intervention 
component may be more or less beneficial, it may  be useful to consider the following: 
o Take a multi-component approach incorporating nutrition, physical activity and 
behaviour change components. 
o Identify high risk groups and ensure services are accessible and appropriate for 
them: can reasonable adjustments be made to improve inclusivity?  
o Co-production: develop interventions with target populations, to tailor the 
intervention to local needs (e.g. language/cultural adaptations; co-morbidity 
management; tailored time, location and delivery style). This may also help reduce 
attrition and poor compliance which can be problematic. 
o Effective communication: how best do you reach your target population and 
referring staff (e.g. available networks, social media, TV, radio, print)? 
o A truly family based approach – ensuring support is in place for all family members 
with weight concerns. 
o The influence of the wider environment (food taxes, availability of healthy food and 
drink; and opportunities to be active), and local systems (personal resources and 
staff training; financial coverage of treatment) 
o Ensure comprehensive systems are in place to record adverse events. 
o The needs of complex families (i.e. families in crisis, child protection issues, severe 
parental or child psychiatric illness) who are unlikely to participate in trials. 
o Consider the scalability of any intervention, and the cost to both to the provider and 
participants. 
o Evaluate and learn from local implementation, by using standardised and validated 
outcome measurement tools. 
 
  538 
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